Back to Authors

Sorenson, Eric

0009-0000-7773-7754

Mayo Clinic

Department of Neurology, Mayo Clinic, Rochester, MN.

Citations 3

Severe Parsonage-Turner Syndrome and Surgically Managed Traumatic Brachial Plexopathy

Neurology | August 28, 2026 | Volume: 107 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000218501 | PMID 42664489

Association of Plasma Neurofilament Light Chain With Diagnostic Classification in a Neuromuscular Referral Cohort

Neurology | July 13, 2026 | Volume: 107 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000218304 | PMID 42441926

Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neuro

Muscle & Nerve | March 8, 2026 | Volume: 73 | Issue: 6 | Pages: 976-983

10.1002/mus.70192 | PMID 41772409

ABSTRACT Background Primary lateral sclerosis (PLS) is an ultrarare upper motor neuron syndrome with a prognosis unique from classical ALS. The study of PLS is complicated by its rarity and the difficulty distinguishing PLS from ALS. We present data from a 1‐year prospective follow‐up study on PLS and efforts to distinguish it from ALS. Methods Seventy‐six PLS participants enrolled in this prospective natural history study. EMG studies, blood neurofilament light chain levels (NfLs), and demographic characteristics were obtained at baseline. At 1‐year follow‐up, repeat EMG studies were conducted to determine which participants fulfilled criteria for ALS. Baseline characteristics were then compared to determine features that predict reclassification. Results Seventy participants completed 1‐year follow‐up. Five of the 70 were reclassified to ALS (7.1%). Those reclassified had higher trends in baseline blood NfL levels (91.4 vs. 34.0 pg/mL, p = 0.13) and shorter symptom duration (39 vs. 69 months in the PLS group, p = 0.15). Reclassification was noted in both probable and definite PLS participants. All cases with a symptomatic duration of less than 2 years retained the PLS phenotype (5 of 5). NfL levels over 90 pg/mL predicted reclassification with 94% specificity and 60% sensitivity. No other features predicted reclassification to ALS. Conclusions In our population, reclassification of PLS to ALS occurred at a low frequency at 1 year follow‐up (7.1%). Baseline NfL was the strongest predictor in differentiating UMN dominant ALS from PLS at 1‐year follow‐up. Based on our data, we propose EMG and NfL criteria for enrollment in future PLS trials.